Enteric fever, predominantly caused by Salmonella typhi and S. paratyphi, continues to pose significant global health challenges. However, advancements in diagnostic methods and treatment strategies have brought about promising changes in managing this infectious disease. This article presents a comprehensive overview of these advancements for healthcare professionals.
Traditional culture methods have been supplemented with serological tests and molecular techniques. The Widal test, though commonly used, suffers from sensitivity and specificity issues. The Typhidot test and Tubex TF test offer better accuracy but are not without limitations. Molecular techniques such as Polymerase Chain Reaction (PCR) and Loop-Mediated Isothermal Amplification (LAMP) have emerged as reliable diagnostic tools, offering rapid, sensitive, and specific detection of S. typhi and S. paratyphi.
Treatment for enteric fever has evolved due to the rising antimicrobial resistance. Fluoroquinolones, the first-line treatment, have seen decreased efficacy due to resistant strains. The World Health Organization now recommends using ceftriaxone or azithromycin as first-line treatments. Vaccination also plays a crucial role in prevention, with the Ty21a and Vi polysaccharide vaccines providing significant protection.
Antimicrobial stewardship programs (ASPs) are increasingly recognized as essential in managing enteric fever. ASPs ensure optimal antibiotic use, minimizing the development of resistance. They also promote the use of rapid diagnostics to guide targeted therapy, reducing unnecessary broad-spectrum antibiotic use.
While challenges persist in managing enteric fever, advancements in diagnostic and treatment strategies offer hope. The integration of molecular diagnostics, new therapeutic guidelines, and antimicrobial stewardship programs can enhance patient outcomes and curb the spread of this infectious disease. It is crucial for healthcare professionals to stay abreast of these developments to provide optimal patient care.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation